Synerrv Atorvastatin Use In Pregnancy & Lactation

Women of childbearing potential: Women of childbearing potential should use appropriate contraceptive measures during treatment.
Pregnancy: Atorvastatin Tablets is contraindicated during pregnancy. Safety in pregnant women has not been established. Rare reports of congenital anomalies following intrauterine exposure to HMG-CoA reductase inhibitors have been received.
Maternal treatment with atorvastatin may reduce the fetal levels of mevalonate which is a precursor of cholesterol biosynthesis. Atherosclerosis is a chronic process, and ordinarily discontinuation of lipid-lowering medicinal products during pregnancy should have little impact on the long-term risk associated with primary hypercholesterolaemia.
For these reasons, Atorvastatin Tablets should not be used in women who are pregnant, trying to become pregnant or suspect they are pregnant. Treatment with Atorvastatin Tablets should be suspended for the duration of pregnancy or until it has been determined that the woman is not pregnant.
Breastfeeding: It is not known whether atorvastatin or its metabolites are excreted in human milk. Because of the potential for serious adverse reactions, women taking Atorvastatin Tablets should not breastfeed their infants. Atorvastatin is contraindicated during breastfeeding.
Fertility: Atorvastatin had no effect on male or female fertility.